

Cyclacel Pharmaceuticals, Inc.  
Form 8-K  
May 07, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 7, 2009**

**CYCLACEL PHARMACEUTICALS, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware  
(State or other jurisdiction  
of incorporation)**

**0-50626  
(Commission File Number)**

**91-1707622  
(IRS Employer  
Identification No.)**

**200 Connell Drive, Suite 1500  
Berkeley Heights, NJ 07922**

**(Address of principal executive offices and zip code)**

**Registrant's telephone number, including area code: (908) 517-7330**

**(Former Name or Former Address, if Changed Since Last Report)**

**Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):**

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)**
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)**
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))**
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))**

**TABLE OF CONTENTS**

Item 8.01 Other Events

Item 9.01 Financial Statements and Exhibits

**SIGNATURES**

**Item 8.01 Other Events**

On May 7, 2009, Cyclacel Pharmaceuticals, Inc. (the **Company** ) issued a press release announcing various upcoming corporate events and that the Company will announce its first quarter 2009 financial results on Thursday, May 14, 2009 and host a conference call and live webcast at 4:30 p.m. Eastern on the same day. Attached as Exhibit 99.1 is a copy of the press release.

**Item 9.01 Financial Statements and Exhibits**

(d) The following exhibit is furnished with this Report:

Exhibit No.	Description
99.1	Press Release dated May 7, 2009

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**CYCLACEL PHARMACEUTICALS, INC.**

By: /s/ Paul McBarron

Name: Paul McBarron

Title: Executive Vice President Finance,  
Chief Financial Officer and  
Chief Operating Officer

Date: May 7, 2009